Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)

NCT01329029 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1945

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Roflumilast
DRUG: Placebo

Sponsor

AstraZeneca